Brokerages Set G1 Therapeutics Inc (GTHX) Target Price at $74.50

G1 Therapeutics Inc (NASDAQ:GTHX) has received an average rating of “Buy” from the eight analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $74.50.

A number of equities research analysts recently weighed in on the stock. BidaskClub cut shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 4th. Needham & Company LLC boosted their price target on shares of G1 Therapeutics to $76.00 and gave the company a “buy” rating in a research report on Tuesday, September 18th. HC Wainwright reissued a “buy” rating and issued a $79.00 price target on shares of G1 Therapeutics in a research report on Monday, September 17th. BTIG Research assumed coverage on shares of G1 Therapeutics in a research report on Monday, September 10th. They issued a “buy” rating and a $80.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price target on shares of G1 Therapeutics from $58.00 to $63.00 and gave the company an “overweight” rating in a research report on Friday, August 10th.

In other news, insider Jay Strum sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $59.60, for a total value of $596,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jennifer K. Moses sold 750 shares of the company’s stock in a transaction dated Monday, August 6th. The shares were sold at an average price of $50.79, for a total transaction of $38,092.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 66,583 shares of company stock valued at $3,614,546. 15.92% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the company. FMR LLC raised its holdings in shares of G1 Therapeutics by 1.2% in the second quarter. FMR LLC now owns 4,902,732 shares of the company’s stock valued at $213,073,000 after buying an additional 57,156 shares during the last quarter. BlackRock Inc. raised its holdings in shares of G1 Therapeutics by 32.0% in the second quarter. BlackRock Inc. now owns 1,690,360 shares of the company’s stock valued at $73,462,000 after buying an additional 409,300 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of G1 Therapeutics by 1,497.7% in the second quarter. Bank of New York Mellon Corp now owns 1,262,991 shares of the company’s stock valued at $54,890,000 after buying an additional 1,183,940 shares during the last quarter. Voya Investment Management LLC raised its holdings in shares of G1 Therapeutics by 7,889.9% in the second quarter. Voya Investment Management LLC now owns 449,834 shares of the company’s stock valued at $19,550,000 after buying an additional 444,204 shares during the last quarter. Finally, BB Biotech AG purchased a new stake in shares of G1 Therapeutics in the second quarter valued at about $15,324,000. 69.17% of the stock is owned by institutional investors and hedge funds.

Shares of GTHX opened at $46.81 on Monday. G1 Therapeutics has a 1-year low of $18.03 and a 1-year high of $69.57. The firm has a market capitalization of $1.75 billion, a P/E ratio of -13.11 and a beta of -1.02.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.01. As a group, equities analysts predict that G1 Therapeutics will post -2.68 EPS for the current year.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Featured Article: Intrinsic Value and Stock Selection

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply